[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Myco Medical Supplies Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":285},{"warningLetters":4,"total":284},[5,32,54,76,96,118,137,157,178,198,219,233,249,271],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},3272,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-25T04:00:00Z\">06\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021\">Davati Medical Supply LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved and Misbranded Product Related to Influenza Virus","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-10142021\">\u003Ctime datetime=\"2021-10-14T04:00:00Z\">10\u002F14\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Herman Cardenas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Davati Medical Supply LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3121 Eagles Nest St., Suite 120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Round Rock\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78665\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@davatimedical.com\"> contact@davatimedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>CBER 21-02\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: June 25, 2021\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Influenza Virus\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\u003C\u002Fp>\n\n\u003Cp>Based on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>Your product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>FDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\u003C\u002Fp>\n\n\u003Cp>• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\u003C\u002Fp>\n\n\u003Cp>• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\u003C\u002Fp>\n\n\u003Cp>• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to correct any violations of the FD&amp;C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Mary A. Malarkey\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nHerman Cardenas\n\nDavati Medical Supply LLC\n\n3121 Eagles Nest St., Suite 120\n\nRound Rock, TX 78665\n\nUnited States\n\ncontact@davatimedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nCBER 21-02\n\nWARNING LETTER\n\nDate: June 25, 2021\n\nRE: Unapproved and Misbranded Product Related to Influenza Virus\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\n\nBased on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nYour product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\n\nFDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\n\nSome examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\n\n• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\n\n• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\n\n• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\n\nYou should take immediate action to correct any violations of the FD&C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\n\nWe advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&C Act. Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMary A. Malarkey\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nU.S. Food and Drug Administration","Davati Medical Supply LLC","davati-medical-supply-llc-615530-06252021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021","2026-10-26T08:08:21.596641+00:00","Warning Letter","Closed Out","2021-07-06","615530","Biologics","2021-10-14","Herman Cardenas","2026-08-20T02:59:22.938+00:00","2021-06-25",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},2257,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","Issued","2023-01-11","647603","Drugs","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":47,"posted_date":69,"marcs_cms_no":70,"product_type":27,"closeout_date":20,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":74,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},21927,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Joe Spell","2026-10-27T01:19:42.766+00:00","VIA UPS and Electronic Mail","CBER 26-727246","2026-10-06",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":47,"posted_date":91,"marcs_cms_no":92,"product_type":50,"closeout_date":20,"issuing_office":82,"recipient_name":20,"body_fetched_at":93,"delivery_method":94,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},472,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","2026-08-19T14:27:25.954+00:00","Via Email","2025-11-13",{"id":97,"raw":98,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":88,"fei_number":20,"letter_url":109,"updated_at":110,"action_type":23,"case_status":47,"posted_date":111,"marcs_cms_no":112,"product_type":113,"closeout_date":20,"issuing_office":102,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":117,"medical_device_id":20,"response_letter_date":20},63,[99,100,101,102,103,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Medical Devices","Jian Xu","2026-08-19T04:32:13.877+00:00","VIA Electronic Mail","2026-05-20",{"id":119,"raw":120,"subject":104,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":128,"fei_number":20,"letter_url":129,"updated_at":130,"action_type":23,"case_status":47,"posted_date":131,"marcs_cms_no":132,"product_type":113,"closeout_date":20,"issuing_office":102,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":20,"reference_number":20,"action_taken_date":136,"medical_device_id":20,"response_letter_date":20},954,[121,122,123,102,104,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","VIA UNITED PARCEL SERVICE","2025-04-04",{"id":138,"raw":139,"subject":143,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":44,"fei_number":20,"letter_url":149,"updated_at":150,"action_type":23,"case_status":24,"posted_date":151,"marcs_cms_no":152,"product_type":113,"closeout_date":153,"issuing_office":102,"recipient_name":154,"body_fetched_at":155,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":156,"medical_device_id":20,"response_letter_date":20},2483,[140,141,142,102,143,13,144,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":158,"raw":159,"subject":163,"body_html":164,"body_text":165,"firm_name":166,"letter_id":167,"created_at":168,"fei_number":20,"letter_url":169,"updated_at":170,"action_type":23,"case_status":47,"posted_date":171,"marcs_cms_no":172,"product_type":27,"closeout_date":20,"issuing_office":60,"recipient_name":173,"body_fetched_at":174,"delivery_method":175,"recipient_title":20,"reference_number":176,"action_taken_date":177,"medical_device_id":20,"response_letter_date":20},21646,[160,161,162,60,163,13,13,13],"\u003Ctime datetime=\"2026-08-25T04:00:00Z\">08\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-14T04:00:00Z\">08\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026\">R3 Medical Companies\u003C\u002Fa>","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-726330\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David L. Greene, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>R3 Medical Companies\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10045 E. Dynamite Blvd., Suite 260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85262\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@bello.bio\"> dgreene@bello.bio\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@regensuppliers.com\"> dgreene@regensuppliers.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-726330\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Greene:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.\u003Cem>\u003Cstrong>\u003Csup>3,4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by \u003Cstrong>(b)(4)\u003C\u002Fstrong> ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>ReBellaWJ:\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> In a November 15, 2020, blog post entitled “\u003Cem>What is Umbilical Cord Wharton’s Jelly\u003C\u002Fem>?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\u003Cbr>• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\u003Cbr>• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\u003Cbr> Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\u003C\u002Fli>\u003Cli>ReBellaXO and ReBellaXOL:\u003Cbr>o Regen website (https:\u002F\u002Fwww.regensuppliers.com):\u003Cbr> Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\u003Cbr> Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, &amp; anti-apoptosis. BelloXO intensely stimulates regeneration…”\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\u003Cbr>• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\u003Cbr>• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\u003C\u002Fli>\u003Cli>ReBellaCB:\u003Cbr>o Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&amp;feature=youtu.be, titled “\u003Cem>Is Umbilical Cord Blood Safe for Regenerative Procedures?\u003C\u002Fem>” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\u003C\u002Fli>\u003Cli>ReBellaCB and ReBellaXO:\u003Cbr>o In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “\u003Cem>Elite Football Player Talks to His Stem Cells (844) GET-STEM\u003C\u002Fem>,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\u003C\u002Fp>\u003Cp>Moreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b).\u003C\u002Fstrong> For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, you have not validated your processes for cleaning and disinfecting the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a).\u003C\u002Fstrong> For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d).\u003C\u002Fstrong> For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\u003C\u002Fp>\u003Cp>Further, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\u003C\u002Fp>\u003Cp>FDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have the following concerns:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\u003C\u002Fli>\u003Cli>FDA review of Bello’s manufacturing records revealed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a component of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been performed prior to the release of these products, as required by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Bello determines donor eligibility upon review of relevant medical records per your contract agreement with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The “\u003Cem>Donor Eligibility Criteria\u003C\u002Fem>” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: \u003Cem>Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products\u003C\u002Fem> (August 2007)\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging &amp; MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-726330\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDavid L. Greene, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nR3 Medical Companies\n\n10045 E. Dynamite Blvd., Suite 260\n\nScottsdale, AZ 85262\n\nUnited States\n\ndgreene@bello.bio\n\ndgreene@regensuppliers.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 14, 2026\nCBER 26-726330\nDear Dr. Greene:\nThe United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.1,2 During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.3,4 Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by (b)(4) ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\nReBellaWJ:\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n In a November 15, 2020, blog post entitled “What is Umbilical Cord Wharton’s Jelly?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\n• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\n• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\n Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\nReBellaXO and ReBellaXOL:\no Regen website (https:\u002F\u002Fwww.regensuppliers.com):\n Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\n Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, & anti-apoptosis. BelloXO intensely stimulates regeneration…”\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\n• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\n• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\nReBellaCB:\no Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&feature=youtu.be, titled “Is Umbilical Cord Blood Safe for Regenerative Procedures?” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\nReBellaCB and ReBellaXO:\no In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “Elite Football Player Talks to His Stem Cells (844) GET-STEM,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\nMoreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\n2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a). For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b). For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, you have not validated your processes for cleaning and disinfecting the ISO (b)(4) biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\n5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a). For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\nThe CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:7\n6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d). For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\nResponses to the Form FDA-483\nWe have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\nFurther, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\nWe acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\nFDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\nAdditional Concerns\nIn addition to the violations described above, we have the following concerns:\nFDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived8 products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\nFDA review of Bello’s manufacturing records revealed that (b)(4) is a component of the (b)(4) used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for (b)(4) had been performed prior to the release of these products, as required by (b)(4).\nBello determines donor eligibility upon review of relevant medical records per your contract agreement with (b)(4). The “Donor Eligibility Criteria” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (August 2007)9 recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: (b)(4)\n________________________\n1 During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\n2 Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging & MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\n3 Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\n4 ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\n5 As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\n6 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\n7 Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\n8 Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\n9 See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.","R3 Medical Companies","r3-medical-companies-726330-08142026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026","2026-10-26T08:09:46.375146+00:00","2026-08-25","726330","David L. Greene, M.D.","2026-09-07T05:15:14.733+00:00","Via UPS and EMAIL","CBER 26-726330","2026-08-14",{"id":179,"raw":180,"subject":185,"body_html":186,"body_text":187,"firm_name":188,"letter_id":189,"created_at":190,"fei_number":20,"letter_url":191,"updated_at":192,"action_type":23,"case_status":47,"posted_date":193,"marcs_cms_no":194,"product_type":50,"closeout_date":20,"issuing_office":82,"recipient_name":20,"body_fetched_at":195,"delivery_method":196,"recipient_title":20,"reference_number":20,"action_taken_date":197,"medical_device_id":20,"response_letter_date":20},3703,[181,182,183,82,184,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026\">D&amp;H Medical Services\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>D&amp;H Medical Services\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 NW 79th Avenue, Suite 265\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@dhmedicalcenter.com\"> info@dhmedicalcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728238\u003C\u002Fp>\u003Cp>To D&amp;H Medical Services:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of D&amp;H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same ingredient as Rybelsus®”\u003C\u002Fli>\u003Cli>“Same ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nD&H Medical Services\n\n2500 NW 79th Avenue, Suite 265\n\nDoral, FL 33122\n\nUnited States\n\ninfo@dhmedicalcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728238\nTo D&H Medical Services:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of D&H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same ingredient as Ozempic®”\n“Same ingredient as Rybelsus®”\n“Same ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","D&H Medical Services","dh-medical-services-728238-06082026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026","2026-10-26T08:08:24.115003+00:00","2026-06-16","728238","2026-08-19T04:34:50.914+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":199,"raw":200,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":210,"fei_number":20,"letter_url":211,"updated_at":212,"action_type":23,"case_status":47,"posted_date":213,"marcs_cms_no":214,"product_type":113,"closeout_date":20,"issuing_office":215,"recipient_name":216,"body_fetched_at":217,"delivery_method":94,"recipient_title":20,"reference_number":20,"action_taken_date":218,"medical_device_id":20,"response_letter_date":20},1506,[201,202,203,204,205,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-29T04:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023\">Spectrum Medical Ltd\u003C\u002Fa>","&quot;OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality&quot;","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steve Turner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spectrum Medical Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Harrier 4, Meteor Business Park, Cheltenham Road East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gloucester, Gloucestershire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>GL2 9QL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 29, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Turner:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved-Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “\u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device\u003C\u002Fu>” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\u003C\u002Fp>\n\n\u003Cp>We discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quantum Pureflow Centrifugal Pumps:\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\u003C\u002Fp>\n\n\u003Cp>The Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\u003C\u002Fp>\n\n\u003Cp>All cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\u003C\u002Fp>\n\n\u003Cp>However, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Roller Pumps and Quantum Power Supply Lite\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\u003C\u002Fp>\n\n\u003Cp>On pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Ventilation Module\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC Tubing Set\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\u003C\u002Fp>\n\n\u003Cp>&nbsp; “use during cardiopulmonary bypass for a duration of up to 6 hours.”\u003C\u002Fp>\n\n\u003Cp>Cardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Charlotte Frame Configuration\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\u003Cbr>\n\u003Cbr>\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\u003C\u002Fp>\n\n\u003Cp>This response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. \u003Cstrong>Refer to CMS case #666543\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, MD\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health for\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nColleen Powell, US Agent\u003Cbr>\nSpectrum Medical Inc\u003Cbr>\n481 Munn Road, Suite 180\u003Cbr>\nFort Mills, SC US 29715\u003Cbr>\nVia Email: Colleen.Powell@spectrummedical.com&gt;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteve Turner\n\nRecipient Title\n\nChief Executive Officer\n\nSpectrum Medical Ltd\n\nHarrier 4, Meteor Business Park, Cheltenham Road East\n\nGloucester, Gloucestershire\n\nGL2 9QL\n\nUnited Kingdom\n\nIssuing Office:\n\n\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nWARNING LETTER\n\nSeptember 29, 2023\n\nDear Mr. Turner:\n\nDuring an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nUnapproved-Device Violations\n\nFDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\n\nWe discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\n\nQuantum Pureflow Centrifugal Pumps:\n\nYour Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\n\nThe Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\n\nAll cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\n\nHowever, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Roller Pumps and Quantum Power Supply Lite\n\nThe Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\n\nThe SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\n\n“intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\n\nOn pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Ventilation Module\n\nOn pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC Tubing Set\n\nOn page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\n\n“use during cardiopulmonary bypass for a duration of up to 6 hours.”\n\nCardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nCharlotte Frame Configuration\n\nOur inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\n\nYour firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\n\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\n\nFor example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the (b)(4) can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\n\n2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\n\nFor example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\n\nThis response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #666543 when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, MD\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health for\n\nCC:\n\nColleen Powell, US Agent\n\nSpectrum Medical Inc\n\n481 Munn Road, Suite 180\n\nFort Mills, SC US 29715\n\nVia Email: Colleen.Powell@spectrummedical.com>","Spectrum Medical Ltd","spectrum-medical-ltd-666543-09292023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023","2026-10-26T08:10:02.82461+00:00","2024-04-30","666543","\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"","Steve Turner","2026-08-20T00:09:37.797+00:00","2023-09-29",{"id":220,"raw":221,"subject":205,"body_html":224,"body_text":225,"firm_name":226,"letter_id":227,"created_at":88,"fei_number":20,"letter_url":228,"updated_at":229,"action_type":23,"case_status":47,"posted_date":193,"marcs_cms_no":230,"product_type":113,"closeout_date":20,"issuing_office":102,"recipient_name":20,"body_fetched_at":231,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":232,"medical_device_id":20,"response_letter_date":20},90,[181,222,223,102,205,13,13,13],"\u003Ctime datetime=\"2026-04-30T04:00:00Z\">04\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026\">ZOLL Medical Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ZOLL Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>269 Mill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chelmsford\u003C\u002Fspan>, \u003Cspan>ME\u003C\u002Fspan> \u003Cspan>01824\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jrennert@zoll.com\"> jrennert@zoll.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 711320\u003C\u002Fp>\u003Cp>April 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Rennert:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.&nbsp;\u003C\u002Fp>\u003Cp>For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\u003C\u002Fp>\u003Cp>For example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which requires a CAPA request per SOP-682.”\u003C\u002Fp>\u003Cp>B. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>i. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\u003C\u002Fp>\u003Cp>ii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, level \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\u003C\u002Fp>\u003Cp>iii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your firm found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports attributed to component failures and additional information on why this did not trigger a CAPA request.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\u003C\u002Fp>\u003Cp>2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\u003C\u002Fp>\u003Cp>A. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the MRI. The vent specification is for \u003Cstrong>(b)(4)\u003C\u002Fstrong> with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\u003C\u002Fp>\u003Cp>B. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when performing the MRI compatibility testing.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\u003C\u002Fp>\u003Cp>3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\u003C\u002Fp>\u003Cp>A. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\u003C\u002Fp>\u003Cp>B. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\u003C\u002Fp>\u003Cp>However, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Legacy, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a probability of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the level of risk will always be considered \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite the level of severity.\u003C\u002Fp>\u003Cp>C. You have failed to assess the risk of visible corrosion spots larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter when within the shelf life of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\u003C\u002Fp>\u003Cp>The adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the investigator during the inspection and have completed the testing and provided the testing in your response.\u003C\u002Fp>\u003Cp>Your firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents in lieu of updating the existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents. What is your rationale for risk acceptability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) determined since your risk categorization appears to be mostly \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for two out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the same hazard of algorithm analysis incorrect but the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> not \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the clinically relevant delay does not contribute to irreversible harm or death.\u003C\u002Fp>\u003Cp>4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> delivered breaths via Real BVM Help, was categorized as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier, which is defined as not directly impacting the production or quality of a device.\u003C\u002Fp>\u003Cp>B. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\u003C\u002Fp>\u003Cp>Your responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> for components used in finished devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\u003C\u002Fp>\u003Cp>Our understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.&nbsp;\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nZOLL Medical Corporation\n\n269 Mill Road\n\nChelmsford, ME 01824\n\nUnited States\n\njrennert@zoll.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711320\nApril 30, 2026\nDear Mr. Rennert:\nDuring an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.\nFor example:\nA. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\nFor example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of (b)(4), which requires a CAPA request per SOP-682.”\nB. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\ni. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\nii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of (b)(4), level (b)(4), as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\niii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\nThe responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “(b)(4)”. Your firm found that (b)(4) out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the (b)(4) reports attributed to component failures and additional information on why this did not trigger a CAPA request.\nWe cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a (b)(4) period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\n2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\nA. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately (b)(4) to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used (b)(4) away from the MRI. The vent specification is for (b)(4) with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\nB. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when performing the MRI compatibility testing.\nThe responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “(b)(4).” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\nWe cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 (b)(4) environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used (b)(4) away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\n3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential (b)(4) and (b)(4) when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\nA. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with (b)(4) employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\nB. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\nHowever, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of (b)(4) for Legacy, (b)(4) for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of (b)(4) and a probability of (b)(4), the level of risk will always be considered (b)(4) despite the level of severity.\nC. You have failed to assess the risk of visible corrosion spots larger than (b)(4) in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as (b)(4) diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than (b)(4) diameter when within the shelf life of (b)(4). Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\nThe adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share (b)(4) with the investigator during the inspection and have completed the testing and provided the testing in your response.\nYour firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new (b)(4) documents in lieu of updating the existing (b)(4) documents. What is your rationale for risk acceptability ((b)(4)) determined since your risk categorization appears to be mostly (b)(4) and (b)(4) for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of (b)(4) for two out of (b)(4) with the same hazard of algorithm analysis incorrect but the (b)(4) hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of (b)(4) not (b)(4) since the clinically relevant delay does not contribute to irreversible harm or death.\n4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\nA. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level (b)(4). The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of (b)(4) delivered breaths via Real BVM Help, was categorized as Level (b)(4). Level (b)(4) suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level (b)(4) supplier, which is defined as not directly impacting the production or quality of a device.\nB. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\nYour responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level (b)(4) and Level (b)(4) for components used in finished devices.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\nThe adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\nOur understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ZOLL Medical Corporation","zoll-medical-corporation-711320-04302026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026","2026-10-26T08:10:39.74889+00:00","711320","2026-08-19T04:37:12.557+00:00","2026-04-30",{"id":234,"raw":235,"subject":238,"body_html":239,"body_text":240,"firm_name":241,"letter_id":242,"created_at":128,"fei_number":20,"letter_url":243,"updated_at":244,"action_type":23,"case_status":47,"posted_date":131,"marcs_cms_no":245,"product_type":113,"closeout_date":20,"issuing_office":102,"recipient_name":246,"body_fetched_at":247,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":248,"medical_device_id":20,"response_letter_date":20},952,[121,236,237,102,238,13,13,13],"\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025\">Noah Medical Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noah Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2075 Zanker Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Jose\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jianzhang@noahmed.com\"> jianzhang@noahmed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #702414\u003C\u002Fp>\u003Cp>April 09, 2025\u003Cbr>\u003Cbr>Dear Ms. Zhang:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\u003C\u002Fp>\u003Cp>a. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\u003C\u002Fp>\u003Cp>b. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\u003C\u002Fp>\u003Cp>a. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\u003C\u002Fp>\u003Cp>i. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\u003C\u002Fp>\u003Cp>ii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\u003C\u002Fp>\u003Cp>iii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\u003C\u002Fp>\u003Cp>b. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\u003C\u002Fp>\u003Cp>c. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\u003C\u002Fp>\u003Cp>i. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\u003C\u002Fp>\u003Cp>ii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\u003C\u002Fp>\u003Cp>Specifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately conduct design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> biopsy tools, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration of the bronchoscope instead of \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\u003C\u002Fp>\u003Cp>b. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\u003C\u002Fp>\u003Cp>i. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\u003C\u002Fp>\u003Cp>ii. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>iii. Protocol #TP-099, Revision B, relating to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations)” and Summary Report #TR-378, Revision A.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\u003C\u002Fp>\u003Cp>a. NCR 0367 (Dated 04\u002F11\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak test due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the working channels (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, your firm did not conduct investigation to identify the root cause(s) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>b. NCR 0605 (Dated 09\u002F20\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures were due to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. NCR 0071 (Dated 07\u002F27\u002F2023) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516 (part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon the “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\u003C\u002Fp>\u003Cp>Your firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nNoah Medical Corporation\n\n2075 Zanker Road\n\nSan Jose, CA 95131\n\nUnited States\n\njianzhang@noahmed.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #702414\nApril 09, 2025\n\nDear Ms. Zhang:\nDuring an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm1. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\na. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\nb. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the (b)(4) poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the (b)(4) aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a (b)(4) aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\na. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\ni. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\nii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\niii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\nb. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\nc. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\ni. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\nii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\nSpecifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.2 For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\na. Your firm failed to adequately conduct design validation for the (b)(4) biopsy tools, such as (b)(4), listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the (b)(4) and used the (b)(4) as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a (b)(4) configuration of the bronchoscope instead of (b)(4) configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\nb. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\ni. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\nii. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\niii. Protocol #TP-099, Revision B, relating to the (b)(4) aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes (b)(4) and (b)(4) configurations)” and Summary Report #TR-378, Revision A.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\na. NCR 0367 (Dated 04\u002F11\u002F2024) involves (b)(4) bronchoscopes failing leak test due to (b)(4) in the working channels (part (b)(4)). However, your firm did not conduct investigation to identify the root cause(s) of the (b)(4) nor implement a SCAR with your supplier.\nb. NCR 0605 (Dated 09\u002F20\u002F2024) involves (b)(4) bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the (b)(4), and the other (b)(4) failures were due to (b)(4). However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed (b)(4).\nc. NCR 0071 (Dated 07\u002F27\u002F2023) involves (b)(4) working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately (b)(4) NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\n5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, (b)(4)” CRB-1516 (part number (b)(4)), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism ((b)(4)) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The (b)(4) were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the (b)(4) upon the “Galaxy, Cart, (b)(4)” CRB-1516.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\nOur inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\nYour firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\n_______________________\n1 FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\n2 Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.","Noah Medical Corporation","noah-medical-corporation-702414-04092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025","2026-10-26T08:09:34.20429+00:00","702414","Jian Zhang","2026-08-19T16:52:23.305+00:00","2025-04-09",{"id":250,"raw":251,"subject":205,"body_html":257,"body_text":258,"firm_name":259,"letter_id":260,"created_at":261,"fei_number":20,"letter_url":262,"updated_at":263,"action_type":23,"case_status":24,"posted_date":264,"marcs_cms_no":265,"product_type":113,"closeout_date":266,"issuing_office":255,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":20,"reference_number":20,"action_taken_date":270,"medical_device_id":20,"response_letter_date":20},2524,[252,253,254,255,205,13,256,13],"\u003Ctime datetime=\"2022-08-09T13:20:00Z\">08\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-12T04:00:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022\">Zyno Medical LLC\u003C\u002Fa>","Office of Medical Devices and Radiological Health Operations Div. 1 East","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintuvie-holdings-llc-629844-07162026\">\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chaoyoung Lee, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zyno Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>177 Pine Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Natick\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01760\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health Operations Div. 1 East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 629844\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 12, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported \u003Cstrong>(b)(4)\u003C\u002Fstrong> over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Approximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures &amp; forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\u003C\u002Fp>\n\n\u003Cp>Your firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>: change in sterilization method&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm waived verification testing for these design changes to the administration sets tubing stating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets were identical to a previous series (B2) of administration sets which had proven durable (\u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\u003C\u002Fli>\n\t\u003Cli>Your firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\u003C\u002Fli>\n\t\u003Cli>Your firm did not perform adequate validation of user needs for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F9\u002F19) and Usability Assessment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Three (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Complaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\u003C\u002Fp>\n\n\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\u003C\u002Fp>\n\n\u003Cp>Additionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>For example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Change in sterilization method from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\u003C\u002Fli>\n\t\u003Cli>Replacement of the spike with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drip chamber. According to your records, these changes were implemented to address new market needs.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph. D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 - East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nChaoyoung Lee, PhD\n\nRecipient Title\n\nCEO & Founder\n\nZyno Medical LLC\n\n177 Pine Street\n\nNatick, MA 01760\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health Operations Div. 1 East\n\nUnited States\n\nWARNING LETTER\n\nCMS# 629844\n\nJuly 12, 2022\n\nDear Dr. Lee:\n\nDuring an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and (b)(4) Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported (b)(4) over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\n\nApproximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\n\nApproximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\n\nApproximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures & forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\n\nYour firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets (b)(4): change in sterilization method (b)(4). For example:\n\nYour firm waived verification testing for these design changes to the administration sets tubing stating that the (b)(4) Administration sets were identical to a previous series (B2) of administration sets which had proven durable ((b)(4); dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\n\nYour firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\n\nYour firm did not perform adequate validation of user needs for (b)(4) administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F9\u002F19) and Usability Assessment for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\n\nSpecifically,\n\nThree (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\n\nFor example:\n\nComplaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nIn each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\nOur inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\n\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\n\nThe adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\n\nYour firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\n\nAdditionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFor example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\n\nChange in sterilization method from (b)(4). While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\n\nReplacement of the spike with (b)(4) and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the (b)(4) and drip chamber. According to your records, these changes were implemented to address new market needs.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThis letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph. D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 - East","Zyno Medical LLC","zyno-medical-llc-629844-07122022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022","2026-10-26T08:10:40.242986+00:00","2022-08-09","629844","2026-07-21","Chaoyoung Lee, PhD","2026-08-20T01:41:20.299+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-07-12",{"id":272,"raw":273,"subject":83,"body_html":275,"body_text":276,"firm_name":277,"letter_id":278,"created_at":88,"fei_number":20,"letter_url":279,"updated_at":280,"action_type":23,"case_status":47,"posted_date":91,"marcs_cms_no":281,"product_type":282,"closeout_date":20,"issuing_office":82,"recipient_name":20,"body_fetched_at":283,"delivery_method":94,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},471,[79,80,274,82,83,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsave-rite-medical-717838-11132025\">Save Rite Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Save Rite Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>168 10th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cs@saveritemedical.com\"> cs@saveritemedical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717838\u003C\u002Fp>\u003Cp>Save Rite Medical:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address www.saveritemedical.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm Ameriwash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, www.saveritemedical.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Antimicrobial…soap with Triclosan…made especially for the healthcare industry…for use in hospitals and nursing homes. •Kills bacteria on contact....” [from your website https:\u002F\u002Fwww.saveritemedical.com\u002Fproducts\u002Fameriwash-antimicrobial-lotion-soap-with-triclosan-1000-ml]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717838” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nSave Rite Medical\n\n168 10th Street\n\nBrooklyn, NY 11215\n\nUnited States\n\ncs@saveritemedical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717838\nSave Rite Medical:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address www.saveritemedical.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm Ameriwash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, www.saveritemedical.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Antimicrobial…soap with Triclosan…made especially for the healthcare industry…for use in hospitals and nursing homes. •Kills bacteria on contact....” [from your website https:\u002F\u002Fwww.saveritemedical.com\u002Fproducts\u002Fameriwash-antimicrobial-lotion-soap-with-triclosan-1000-ml]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717838” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Save Rite Medical","save-rite-medical-717838-11132025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsave-rite-medical-717838-11132025","2026-10-26T08:09:54.256802+00:00","717838","Drugs Over-the-Counter Drugs","2026-08-19T14:27:43.585+00:00",14,{"510k":286,"classification":287,"enforcement":288,"event":289,"event_backfill":290,"pma":291,"warning_letter":292},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]